Vous avez cherché: diarejo (Slovène - Anglais)

pertuzumab lahko izzove hudo diarejo.
pertuzumab may elicit severe diarrhoea.

koristno simptomatično uravnava diarejo in kolitis.
provides useful symptomatic management of diarrhoea and colitis.

klinični znaki so bili omejeni na pruritus in diarejo.
clinical features were limited to pruritus and diarrhoea.

zato je diarejo treba vključiti v poglavje 4.8 smpc.
therefore, diarrhoea should be included in section 4.8 of the smpc.

gastrointestinalni simptomi (vključno z diarejo, bruhanjem in navzeo)
gastrointestinal symptoms (including diarrhoea, vomiting and nausea)

dehidracija, na splošno povezana z navzeo, bruhanjem in/ali diarejo
dehydration, generally associated with nausea, vomiting and/or diarrhoea.

v tem primeru bi na podlagi statističnih podatkov polovica prisotnih trpela za diarejo.
then statistics would actually say that half of you would now be suffering with diarrhea.

bolnik je dobil diarejo, postal razdražljiv in je razvil metabolično acidozo s hipokaliemijo.
the patient developed diarrhoea, irritability and metabolic acidosis with hypokalaemia.

akutni znaki prevelikega odmerjanja lahko vključujejo navzeo, bruhanje, glavobol in diarejo.
acute signs of overdose may include nausea, vomiting, headache and diarrhoea.

dodatno zdravljenje bo lahko potrebno (določi ga veterinar) pri živalih z diarejo.
additional treatment (by a veterinarian) may be needed in animals with diarrhoea.

da ne bi prišlo do čezmerne izgube telesne mase, je pri bolnikih z diarejo priporočljivo spremljanje telesne mase.
for patients experiencing diarrhoea, a follow-up of weight is recommended in order to avoid potential excessive weight decrease.

uporabo zdravila pogosto povezujejo z neželenimi učinki na prebavila, vključno z navzeo, bruhanjem in diarejo.
its use is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting, and diarrhoea.

poleg tega lahko opazimo okužbo s povišano telesno temperaturo ali brez nje, diarejo in/ali vnetje sluznic.
in addition, infection with or without fever, diarrhoea, and / or mucositis may be seen.

presnovne in prehranske motnje: dehidracija, na splošno povezana z navzeo, bruhanjem in/ ali diarejo.
metabolism and nutritional disorders: dehydration, generally associated with nausea, vomiting and/ or diarrhoea.

omenjeno reakcijo je treba upoštevati pri diferencialni diagnostiki primerov s hudo ali perzistirajočo diarejo, ki se pojavi med ali le kratek čas po zdravljenju s paklitakselom.
this reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel.

bolnike s kronično diarejo ali drugimi trdovratnimi prebavnimi težavami, ki se na te ukrepe ne odzovejo, je treba preiskati skladno s klinično prakso.
patients with chronic diarrhoea or other persistent gastrointestinal events that do not respond to these interventions should be investigated according to clinical practice.

2reakcije, povezane z infundiranjem, so pri bolnikih s sjia med drugimi vključevale kožni izpuščaj, urtikarijo, diarejo, nelagodje v epigastriju, artralgijo in glavobol.
infusion related reaction events in sjia patients included but were not limited to rash, urticaria, diarrhoea, epigastric discomfort, arthralgia and headache

od 681 (78 %) bolnikov, ki so imeli diarejo, jih je 665 imelo z zdravilom povezan nastanek diareje in 8 bolnikov je zaradi diareje prekinilo zdravljenje z bosutinibom.
of the 681 (78%) patients that experienced diarrhoea, 665 patients had drug-related events of diarrhoea and 8 patients discontinued bosutinib due to this event.

pri več kot 80 % bolnikov so na začetku zdravljenja ali občasno med zdravljenjem opažali neželene učinke na prebavila, zlasti diarejo (glejte poglavje 4.8).
gastrointestinal events, mainly diarrhoea, have been observed in more than 80% of patients, either at the outset of treatment or intermittently during treatment (see section 4.8).

s testom izolacije virusa (s fluorescenčnim testom za protitelesa ali z imunoperoksidaznim testom) glede na govejo virusno diarejo, ki je bil za mlajše živali odložen, dokler niso dosegle starosti šestih mesecev;
a virus isolation test (fluorescent antibody test or immunoperoxidase test) for bovine viral diarrhoea, deferred until the animal reached the age of six months in the case of younger animals;